
- Oncology NEWS International Vol 12 No 2
- Volume 12
- Issue 2
Advexin p53 Therapy Plus RT Shows Lung Tumor Regression
HOUSTON-Introgen Therapeutics, Inc. has published data from its phase II study combining Advexin, an adenoviral vector containing the p53 tumor-suppressor gene, with radiation therapy in patients with nonmetastatic non-small-cell lung cancer (NSCLC) (Clinical Cancer Research, January 2003). The patients were ineligible to receive surgery or combination therapy with radiation and chemotherapy.
HOUSTONIntrogen Therapeutics, Inc. has published data from its phase II study combining Advexin, an adenoviral vector containing the p53 tumor-suppressor gene, with radiation therapy in patients with nonmetastatic non-small-cell lung cancer (NSCLC) (Clinical Cancer Research, January 2003). The patients were ineligible to receive surgery or combination therapy with radiation and chemotherapy.
Advexin was delivered via injection into the tumor. Three months after treatment, biopsies showed no viable tumor cells in 63% of patients. Radiographic assessment of the primary tumor likewise showed that 63% of patients had a major response. The study was conducted at M.D. Anderson Cancer Center with Stephen Swisher, MD, as principal investigator.
Articles in this issue
over 22 years ago
Some Activity for Gefitinib in Heavily Pretreated Breast Cancerover 22 years ago
Brachytherapy Results Similar for Blacks, Whitesover 22 years ago
Dose-Dense Chemo Ups Survival in Node+ Breast Cancerover 22 years ago
MR Spectroscopy IDs Breast Cancers, Node Involvementover 22 years ago
ODAC Wants More Data on Expanded Casodex Indicationover 22 years ago
SuperGen Submits First NDA Module for Pancreatic Cancer Drugover 22 years ago
Two Added to ONI’s Oncology Nursing Editorial Advisory Boardover 22 years ago
Bortezomib Active in Relapsed/Refractory Myelomaover 22 years ago
Telomerase Potential Cancer BiomarkerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.